Faculty

Carrie A. Schinstock, M.D.

Clinical Studies

A Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody-mediated Rejection in Kidney Transplant Recipients (IMAGINE) Rochester, Minn., Scottsdale/Phoenix, Ariz.
The purpose of this study is to investigate whether clazakizumab (an anti-interleukin (IL)-6 monoclonal antibody (mAb)) may be beneficial for the treatment of CABMR in recipients of a kidney transplant by inhibiting the production of Donor Specific Antibodies (DSA) and re-shaping T cell alloimmune responses.

Analysis of Urinary Exosomes in Healthy Kidney Donors and Renal Transplant Recipients Rochester, Minn.
The purpose of this study is to use urinary exosomes to non-invasively identify (protein biomarkers) various conditions affecting the renal transplant.

Alloimmune T-Cell Responses in Highly Sensitized Kidney Transplant Recipients: A Pilot Study Rochester, Minn., Scottsdale/Phoenix, Ariz.
The purpose of this study is to better understand how the immune system reacts to kidney transplantation in individuals who are potentially at higher risk for rejection.
Identifying Physical Function Trajectories and Biomarkers after Kidney Transplantation Rochester, Minn., Jacksonville, Fla., Scottsdale/Phoenix, Ariz.
The aims of this study are to identify frailty trajectories and biomarkers of frailty after kidney transplantation. Subjects will be followed beginning immediately prior to kidney transplantation until 1 year after kidney transplantation. Frailty will be prospectively assessed using performance-based measures (Fried criteria and Short Physical Impairment Battery). The relationship between frailty measures and blood levels of promising candidate biomarkers will be analyzed.